Operational Costs Compared: SG&A Analysis of GSK plc and Genmab A/S

A Decade of SG&A Evolution: GSK plc vs. Genmab A/S

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, GSK plc and Genmab A/S have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. GSK plc, a stalwart in the industry, has consistently maintained high SG&A costs, peaking in 2020 with a 39% increase from 2014. In contrast, Genmab A/S, a rising star, has seen its SG&A expenses skyrocket by over 4,000% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies.

The data reveals a pivotal shift in 2022, where Genmab's SG&A expenses surged by 109% compared to the previous year, highlighting its rapid growth phase. Meanwhile, GSK's expenses dipped by 27% in the same year, possibly indicating strategic cost optimization. This analysis underscores the dynamic nature of operational strategies in the pharmaceutical sector, where adaptability and foresight are key.